Clinical results of Perftoran application: present and future.

Clinical experience of Perftoran (commercial drug of low concentrated perfluorocheminal emulsion) applications is presented in some statistical data and in brief analysis of clinical trials and following clinical studies described in the Russian scientific literature. Observed data allow us to suppose that Perftoran facilitates oxygen delivery together with remaining red blood cells at blood replacements and will have more wider area for application than just a blood substitute. Its infusion alleviates symptoms of ischemia at different types of occlusion vessels disease, improves grafting in plastic surgery, diminishes inflammation and prevents rejection of transplants, activates detoxication functions of liver, inhibits retro-virus infection development.

[Effects of blood substitutes of different pharmacological groups and the mode of their injection on the bloodflow of rats].

Central and peripheral bloodflow before and after intramuscular and intravenous injections of 0.9% NaCl (control groups, n=20) and perfluothane (n=20) in a dose of 5 ml/kg was studied in 40 Wistar rats. Dopplerographic study of the bloodflow was carried out on a diagnostic device Biomedical AU-5 (Italy).